Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

RAY1225

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Guangdong Raynovent Biotech Co · Phase 3 · Recruiting · Enrollment 640

NCT06893016

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
RAY1225 High Dosen/rn/rn/rn/r
RAY1225 Medium Dosen/rn/rn/rn/r
RAY1225 Low Dosen/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • RAY1225 High Dose: endpoint not reported
  • RAY1225 Medium Dose: endpoint not reported
  • RAY1225 Low Dose: endpoint not reported
  • Placebo: endpoint not reported